公司資料
DexCom, Inc. 股價、新聞與催化劑
- 股票代碼:
- DXCM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
88.76 USD (-1.10%)
收盤價
最後更新: 2026年8月17日
28.3B USD
市值
股價為何變動
As of Aug 17, 2026, DXCM closed down 1.10% at $88.76. No new same-company headline was identified in the current news window.
公司概覽
業務概覽
DexCom is a leading medical technology company focused on continuous glucose monitoring for diabetes care. The company’s platform is built around connected sensors, recurring usage, and the expansion of CGM across broader patient populations.
所在地與產業分類
Headquartered in the United States and listed on NASDAQ, DexCom is a healthcare technology company with strong exposure to diabetes monitoring. It sits in device-driven chronic care rather than drug development.
商業模式特徵
DexCom generates revenue through sensor sales, platform adoption, and recurring glucose-monitoring usage. Investors track user growth, reimbursement, product launches, and whether the company can keep extending CGM beyond its core base.
生技產業定位
DexCom is not biotech proper, but it is one of the most important diabetes technology names in healthcare. It is more about device adoption and recurring use than binary clinical or FDA-drug events.
未來催化劑
- Dexcom’s watchlist is G7 adoption, international expansion, and sensor-cycle execution that supports recurring revenue. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。